13F Holdings
中文EN

CMND Clearmind Medicine Inc. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1892500 · Fiscal year ends 10/31

Financial factors as of 2026-01-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-33.9%
TTM EPS YoY68.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-119.7%
ROA-74.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.1%
Debt / equity0.00x
Current ratio3.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-12.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-10-31 · USDFY2024*2024-10-31 · USDFY2023*2023-10-31 · USDFY2022*2022-10-31 · CADFY2021*2021-10-31 · CAD
Income statement
Revenue—————
R&D expense$2.06M$1.38M$1.54M4.21M646,487
SG&A expense$3.61M$4.36M$4.76M4.33M3.03M
Operating income———-8.53M-3.68M
Interest expense$3,857$5,386—19,67833,528
Pretax income-$3.79M-$4.88M-$8.60M-9.37M-3.72M
Income tax$70,445$377,966$17,37240,754—
Net income-$3.86M-$5.25M-$8.62M-9.41M-3.72M
EPS (basic)-30.35-67.80-1,703.04-7.24-4.01
EPS (diluted)-30.35-67.80-1,703.04-7.24-4.01
Weighted avg. shares (diluted)127,09377,5035,06243,33530,911
Balance sheet
Cash & equivalents$3.92M$6.57M$5.43M175,7684.60M
Short-term investments$1.66M$289,388$86,112——
Receivables———69,518160,866
Current assets$5.95M$7.09M$5.79M593,3124.92M
PP&E, netmay include right-of-use assets (IFRS)——$1,72717,61020,578
Intangibles$97,372$108,326$119,310177,797198,039
Total assets$6.08M$7.26M$5.95M1.13M5.16M
Current liabilities$4.89M$4.13M$4.97M——
Total liabilities$4.89M$4.15M$4.97M2.64M357,155
Shareholders' equity$1.19M$3.11M$983,472-$1.11MUSD4.80M
Shares outstanding———43,9921.25M
Cash flow statement
Operating cash flow-$4.73M-$4.86M-$6.30M-5.08M-2.84M
Capital expenditure———7,59323,150
Free cash flow———-5.09M-2.86M
Investing cash flow-$542,017-$238,097-$26,228-7,593-251,189
Financing cash flow$2.62M$6.25M$11.66M698,4037.36M
Stock-based compensation$805,890$998,918$834,813788,657692,155

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.